What are the second-line treatment options for a patient with drug-resistant tuberculosis (TB), considering their medical history and potential drug interactions?

Second-Line Anti-TB Medications for Drug-Resistant Tuberculosis

For drug-resistant TB, build regimens using a hierarchical drug selection approach: Group A drugs (levofloxacin/moxifloxacin, bedaquiline, and linezolid) form the mandatory backbone, supplemented with Group B drugs (clofazimine, cycloserine/terizidone) to achieve at least 4-5 effective medications throughout treatment. 1, 2, 3

Core Regimen Construction

Group A Drugs (Include All Three If Possible)

• Levofloxacin 750-1000 mg daily OR moxifloxacin 400 mg daily (levofloxacin preferred due to fewer adverse events and less QTc prolongation) 1, 2
• Bedaquiline 400 mg daily for 2 weeks, then 200 mg three times weekly for at least 22 weeks (can extend beyond 6 months with careful monitoring) 1, 2
• Linezolid 600 mg daily (reduce to 300 mg daily if myelosuppression or neuropathy develops) 1, 2

Group B Drugs (Add At Least One)

• Clofazimine 100 mg daily 1, 2
• Cycloserine or terizidone 10-15 mg/kg daily (maximum 1000 mg) 1, 2

Group C Drugs (Add If Needed to Reach 4-5 Effective Drugs)

• Ethambutol (if susceptible) 2, 3
• Delamanid 3
• Pyrazinamide (if susceptible) 2, 3
• Ethionamide/prothionamide (only if documented susceptibility; note cross-resistance with isoniazid via inhA mutations) 2, 3
• Para-aminosalicylic acid 3

Special Regimen Options

Shorter All-Oral Regimen (9-12 Months)

Use only in eligible patients: no prior second-line drug exposure >1 month, confirmed fluoroquinolone susceptibility, and no extensive disease 4, 2

• Bedaquiline, levofloxacin/moxifloxacin, clofazimine, pyrazinamide, ethambutol, high-dose isoniazid, and ethionamide/prothionamide for 9-11 months 2, 3

BPaL Regimen (6-9 Months)

For fluoroquinolone-resistant MDR-TB under operational research conditions: bedaquiline, pretomanid, and linezolid with ≤2 weeks prior exposure to bedaquiline/linezolid 4

Critical Management Principles

Drug Selection Rules

• Never add only one effective drug to a failing regimen—this accelerates resistance amplification 2, 3
• Use only drugs with documented susceptibility or high likelihood of susceptibility based on drug susceptibility testing (DST) 4, 2, 3
• Maintain at least 3-4 effective drugs throughout treatment, even after bedaquiline discontinuation 1
• Perform second-line DST to confirm resistance patterns before finalizing regimen 3, 5

Drugs to Avoid or Use Cautiously

• Do NOT use kanamycin or capreomycin in MDR/RR-TB regimens 1
• Injectable agents (amikacin, streptomycin) only when isolate is documented susceptible AND five effective oral drugs cannot be assembled 1, 2
• High-dose isoniazid can be considered with low-level resistance but NOT with high-level resistance 2

Treatment Duration

• Standard longer regimen: 18-20 months from start OR 15-17 months after culture conversion, whichever is longer 1
• Bedaquiline duration: typically 24 weeks (6 months), extendable if necessary 1
• Shorter regimen: 9-12 months total 4

Monitoring Requirements

Baseline and Ongoing Assessments

• ECG: baseline and monthly to detect QTc prolongation (bedaquiline, clofazimine, fluoroquinolones all prolong QT interval) 4, 1
• Complete blood count: monthly to detect linezolid-induced myelosuppression 1
• Visual acuity and color vision: regular evaluation for optic neuropathy (ethambutol, linezolid) 1
• Sputum culture: monthly to monitor treatment response 4, 3
• Renal function: monitor with aminoglycosides if used 4
• Hepatic function: monitor with ethionamide, para-aminosalicylic acid 4

Key Toxicity Profiles and Drug Interactions

Overlapping Toxicities to Avoid

• QTc prolongation: fluoroquinolones, bedaquiline, delamanid, clofazimine (avoid combining multiple QT-prolonging agents when possible) 4
• Peripheral neuropathy: linezolid, cycloserine, ethionamide (give pyridoxine 100-200 mg daily with cycloserine) 4
• Myelosuppression: linezolid (dose reduction to 300 mg may be necessary) 4, 1
• Nephrotoxicity: aminoglycosides, capreomycin 4
• Hepatotoxicity: ethionamide, para-aminosalicylic acid 4
• CNS effects: cycloserine (psychosis, seizures—more common at doses >500 mg/day) 4

HIV Co-infection Considerations

• Start antiretroviral therapy within first 8 weeks of anti-TB treatment initiation, regardless of CD4 count 4, 3
• Monitor for drug-drug interactions: bedaquiline and delamanid metabolized via CYP450 (interactions with protease inhibitors, efavirenz) 4
• Patients with HIV and MDR-TB have up to fourfold higher mortality risk 4

Common Pitfalls to Avoid

• Do not use fixed-dose combinations for drug-resistant TB—individual drug dosing is essential 4
• Do not continue ineffective drugs based on in vitro or molecular DST results 4
• Do not treat without expert consultation—MDR-TB management requires multidisciplinary team involvement 3
• Do not ignore minor adverse effects—they predict non-adherence and treatment failure if unmanaged 6, 7
• Do not delay second-line DST—it substantially improves outcomes and prevents resistance amplification 5